2021-10-15| Asia-Pacific

Dr. Reddy Stands as the First Indian Firm to Launch Cancer Drug in Chinese Market

by Tyler Chen
Share To

India’s Dr. Reddy’s Laboratories has made history as the first Indian firm to receive approval from China for an anticancer drug.

India’s Ambassador to China Vikram Misri tweeted on October 13, “a breakthrough for the Indian pharmaceutical industry in China as Abiraterone by Dr. Reddy’s Laboratories becomes the first anti-cancer drug from India to enter the Chinese market. Expect more success on this front.”

Generic Version of Janssen’s Zytiga


Dr. Reddy’s anti-cancer drug is a generic version of Janssen’s abiraterone acetate (Zytiga). Zytiga was approved by USFDA in February 2018 to be used in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). What’s more, the drug was approved in China in 2015 as a combination therapy to treat patients with mCRPC.

Statistics have shown that sales of abiraterone acetate substantially increased from 2016 to 2019. The annual sales revenue reached $88 million in 2019, a 30-fold jump in revenue compared to 2016. A report by ​​Research and Markets estimates sales of abiraterone in China “will continue to grow” in the next five years as the outlook of the Covid-19 pandemic improves. 

Dr. Reddy’s Moves on Cancer Drugs


In September 2021, Dr. Reddy launched Reddy-Lenalidomide, the generic version of Celgene’s oral cancer drug Revlimid, in Canada. It is one of the first generics of Revlimid in Canada, and it is used to treat patients with multiple myeloma.

The same month, the Indian firm sold the rights of its anti-cancer agent E7777 to Citius Pharmaceuticals, the deal of which is worth up to $150 million including  milestone payments. Dr. Reddy’s Laboratories acquired the drug in 2016 from the Japanese biotech Eisai.

© All rights reserved. Collaborate with us:
Related Post
GeneOnline’s Weekly News Highlights: July 31-Aug 4
GeneOnline’s Weekly News Highlights: June 12-16
Should People Looking to Lose Weight Skip Sugar Substitutes?
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
BioFuture 2023
New York city,USA
Scroll to Top